Literature DB >> 18287880

Distinct role of nox1, nox2, and p47phox in unstimulated versus angiotensin II-induced NADPH oxidase activity in human venous smooth muscle cells.

Olivier Chose1, Patricia Sansilvestri-Morel, Cécile Badier-Commander, Fabienne Bernhardt, Jean-Noël Fabiani, Alain Rupin, Tony J Verbeuren.   

Abstract

Human saphenous veins (SV) are used for coronary bypass surgery despite the higher rate of graft failure observed as compared to arteries. A higher production of reactive oxygen species (ROS) in SV than in internal mammary artery (IMA) has been incriminated as possibly implicated in graft failure. NADPH oxidase, involved in vascular ROS production, was therefore characterized in human smooth muscle cells from SV. ROS production was confirmed to be essentially NADPH oxidase dependent in cultured smooth muscle cells (SMC) from human SV and increased in comparison with IMA. To investigate the role of NADPH oxidase subunits, siRNA for nox1, nox2, or p47 mRNA were studied. In cultured venous SMC under unstimulated conditions, inhibition of nox1 or nox2 mRNA decreased ROS production, whereas p47 silencing increased it. During angiotensin II (AngII) activation, nox2 or p47 mRNA silencing decreased ROS production, while nox1 inhibition had no effect. Venous SMC express functional nox1 and nox2. Only nox2 is implicated in response to AngII whilst nox1 is involved in unstimulated ROS production. p47 negatively regulates ROS generation under basal conditions, whereas it enhances AngII increased ROS production. Thus, nox1, nox2, and p47 have distinct roles in NADPH oxidase activity in human veins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287880     DOI: 10.1097/FJC.0b013e31815d781d

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  NOX Modifiers-Just a Step Away from Application in the Therapy of Airway Inflammation?

Authors:  Joanna Wieczfinska; Milena Sokolowska; Rafal Pawliczak
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

2.  p47(phox) is required for afferent arteriolar contractile responses to angiotensin II and perfusion pressure in mice.

Authors:  En Yin Lai; Glenn Solis; Zaiming Luo; Mattias Carlstrom; Kathryn Sandberg; Steven Holland; Anton Wellstein; William J Welch; Christopher S Wilcox
Journal:  Hypertension       Date:  2011-12-19       Impact factor: 10.190

Review 3.  Redox regulation of Nox proteins.

Authors:  Srikanth Pendyala; Viswanathan Natarajan
Journal:  Respir Physiol Neurobiol       Date:  2010-09-29       Impact factor: 1.931

Review 4.  Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins.

Authors:  Srikanth Pendyala; Peter V Usatyuk; Irina A Gorshkova; Joe G N Garcia; Viswanathan Natarajan
Journal:  Antioxid Redox Signal       Date:  2009-04       Impact factor: 8.401

5.  Requirement of NOX2 and reactive oxygen species for efficient RIG-I-mediated antiviral response through regulation of MAVS expression.

Authors:  Anton Soucy-Faulkner; Espérance Mukawera; Karin Fink; Alexis Martel; Loubna Jouan; Yves Nzengue; Daniel Lamarre; Christine Vande Velde; Nathalie Grandvaux
Journal:  PLoS Pathog       Date:  2010-06-03       Impact factor: 6.823

Review 6.  The impact of age-related dysregulation of the angiotensin system on mitochondrial redox balance.

Authors:  Ramya Vajapey; David Rini; Jeremy Walston; Peter Abadir
Journal:  Front Physiol       Date:  2014-11-24       Impact factor: 4.566

Review 7.  Beyond the Extra Respiration of Phagocytosis: NADPH Oxidase 2 in Adaptive Immunity and Inflammation.

Authors:  Paige M Mortimer; Stacey A Mc Intyre; David C Thomas
Journal:  Front Immunol       Date:  2021-09-01       Impact factor: 7.561

8.  Pregnancy-associated venous insufficiency course with placental and systemic oxidative stress.

Authors:  Miguel A Ortega; Beatriz Romero; Ángel Asúnsolo; Clara Martínez-Vivero; Felipe Sainz; Coral Bravo; Juan De León-Luis; Melchor Álvarez-Mon; Julia Buján; Natalio García-Honduvilla
Journal:  J Cell Mol Med       Date:  2020-03-06       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.